Delve into the world of ANGPTL3 inhibition and its impact on lipid profiles in this interview with Robert Rosenson, MD, of Icahn Mount Sinai. Filmed around the European Atherosclerosis Society 2024 Congress, the conversation centers around reductions in cholesterol levels with evinacumab and the promising advancements with zodasiran.
Join us as we explore the future of cardiovascular therapy and the implications for patients with severe hypercholesterolemia.
Full article: www.hcplive.com/view/robert-r...
#lipidprofiles #cardiovascularhealth #hypercholesterolemia #clinicaltrials